MicrobiomeX (Citrus Flavonoids)

MicrobiomeX is a patented citrus flavonoid extract standardized to hesperidin and naringenin that selectively promotes beneficial gut bacteria by acting as a prebiotic substrate, driving short-chain fatty acid (SCFA) production. Its primary mechanism involves colonic fermentation of flavonoid polyphenols, which shifts the microbiome composition toward Lactobacillus and Bifidobacterium species while suppressing potentially harmful bacteria.

Origin & History

MicrobiomeX is a branded ingredient consisting of flavonoid extracts derived from Citrus sinensis (immature oranges) and Citrus paradisi (grapefruit) peels, a byproduct of citrus fruit processing. The extraction process typically involves ultrasound-assisted methods with 52-80% ethanol or heated aqueous extraction at basic pH (7-12), followed by purification on XAD-16 macroporous resin.

Historical & Cultural Context

While MicrobiomeX itself has no specific historical use, citrus peels have been used in Traditional Chinese Medicine for centuries, particularly chenpi (dried tangerine peel), to treat digestive issues, cough, and inflammation. These traditional applications are attributed to the flavonoid and polyphenol content found in citrus peels.

Health Benefits

• Promotes beneficial gut bacteria growth and SCFA production (preliminary evidence from in vitro studies only)
• May support digestive health through microbiome modulation (based on in vitro fermentation studies)
• Exhibits antioxidant properties via free radical scavenging (demonstrated in laboratory assays)
• Shows anti-inflammatory potential (in vitro evidence only)
• May enhance production of beneficial short-chain fatty acids including butyric acid (in vitro data)

How It Works

MicrobiomeX delivers hesperidin and naringenin, which resist upper gastrointestinal absorption and reach the colon intact, where they serve as fermentable substrates for saccharolytic bacteria. Microbial metabolism converts these flavanones into smaller phenolic metabolites such as hesperetin and protocatechuic acid, which inhibit NF-κB signaling and reduce pro-inflammatory cytokine expression in colonocytes. Concurrently, increased SCFA output—particularly butyrate and propionate—activates GPR41 and GPR43 free fatty acid receptors on intestinal epithelial cells, reinforcing tight junction integrity and supporting mucosal barrier function.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on MicrobiomeX are available. Current evidence is limited to in vitro studies using citrus peel flavonoid extracts from various cultivars (n=14) showing modulation of intestinal microbiota and SCFA production in simulated fermentation models. No PMIDs for MicrobiomeX-specific human trials are documented.

Clinical Summary

Human evidence for MicrobiomeX specifically is limited, with most mechanistic data derived from in vitro fecal fermentation studies demonstrating increased Bifidobacterium and Lactobacillus counts and elevated SCFA concentrations. A small-scale in vitro batch fermentation study using the proprietary citrus extract showed a statistically significant increase in butyrate production compared to inulin controls, though this has not been replicated in large randomized controlled trials. Broader research on dietary citrus flavonoids in human trials (n=20–60) suggests modest but measurable improvements in gut microbiome diversity and reduced markers of intestinal permeability, but these findings cannot be directly extrapolated to MicrobiomeX's specific formulation and dosage. The overall evidence is preliminary and promising but insufficient to establish definitive clinical endpoints without larger, placebo-controlled human trials.

Nutritional Profile

MicrobiomeX is a standardized citrus flavonoid extract, primarily derived from sweet orange (Citrus sinensis) and/or other citrus species. It is not a macronutrient source and provides negligible calories, protein, fat, or digestible carbohydrates at typical serving sizes (250–500 mg/day). Key bioactive compounds include: • Hesperidin (primary flavanone glycoside, typically standardized to ≥80–90% of total flavonoid content; approximately 200–450 mg per serving depending on product specification) • Naringin (secondary flavanone glycoside, present at lower concentrations, typically 5–15% of extract) • Minor citrus polymethoxyflavones (PMFs) such as nobiletin and tangeretin (trace to ~2–5% of extract) • Additional phenolic acids and flavonoid glycosides in small quantities. The extract is rich in polyphenolic compounds with total flavonoid content generally exceeding 90% by weight in high-quality preparations. Bioavailability notes: Citrus flavanone glycosides like hesperidin have relatively low oral bioavailability in the upper GI tract (estimated <5% absorption intact); however, they are extensively metabolized by colonic microbiota to bioactive aglycones (hesperetin, naringenin) and phenolic acid metabolites, which are then absorbed. This colonic metabolism is central to MicrobiomeX's proposed mechanism of action — the flavonoids serve as substrates/prebiotics for beneficial gut bacteria (particularly Bifidobacterium and Lactobacillus spp.), which ferment them into short-chain fatty acids (SCFAs: acetate, propionate, butyrate). The rutinoside form of hesperidin requires bacterial rhamnosidase for deglycosylation, meaning bioactivity is microbiome-dependent and varies between individuals. No significant vitamin or mineral content is present. Dietary fiber content is negligible (<1 g per serving). The product functions as a targeted polyphenol-based prebiotic rather than a conventional nutritional supplement.

Preparation & Dosage

No clinically studied dosage ranges are available for MicrobiomeX as no human trials have been conducted. In vitro fermentation studies used 0.10 g/ml concentrations, but this cannot be translated to human dosing recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Prebiotics, Digestive Enzymes, L-Glutamine, Zinc Carnosine

Safety & Interactions

MicrobiomeX is generally considered well-tolerated at typical supplemental doses of 500–1000 mg per day, with mild gastrointestinal side effects such as bloating or loose stools reported occasionally as the gut microbiome adjusts. Hesperidin, a primary active compound, can inhibit CYP3A4 and P-glycoprotein activity, creating a potential interaction with medications metabolized by these pathways, including statins, calcium channel blockers, and cyclosporine. Naringenin has demonstrated mild estrogenic activity in preclinical models, so individuals with hormone-sensitive conditions or those on hormonal therapies should consult a healthcare provider before use. Safety data during pregnancy and lactation is insufficient, and use is not recommended during these periods without medical supervision.